PFE Dec 2024 28.000 put
- Reuters
Pfizer's Paxlovid fails as 15-day treatment for long COVID, study finds
A 15-day course of Pfizer's COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers. Currently, there are no proven treatments specifically for long COVID in which a host of symptoms can last for many months after initial coronavirus infection. Scientists and patients had hoped that Pfizer's two-drug oral treatment would ease symptoms of long COVID after anecdotal reports of patients who said Paxlovid helped them.
- Zacks
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Data from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
- Investor's Business Daily
Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?
Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?
